Regeneron 'Kickbacks' Boosted Eylea Profits, Insurer Says
Regeneron Pharmaceuticals has illegally cornered the market for an eye disease treatment over a competitor's cheaper drug in a kickback scheme with a charity, reaping billions of dollars in annual revenue...To view the full article, register now.
Already a subscriber? Click here to view full article